|

Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

RECRUITINGPhase 2Sponsored by NewAmsterdam Pharma
Actively Recruiting
PhasePhase 2
SponsorNewAmsterdam Pharma
Started2026-09
Est. completion2028-09
Eligibility
Age55 Years – 85 Years
Healthy vol.Accepted
Locations1 site

Summary

A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease

Eligibility

Age: 55 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria:

* participants with preclinical AD

Exclusion Criteria:

* APOE genotype not meeting protocol-defined eligibility criteria

Conditions2

Alzheimer's DiseasePreclinical Alzheimer's Disease

Interventions2

Locations1 site

K2 Medical Research
Victoria Marsh615-208-K2K2 (5252)victoria.marsh@k2med.com

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.